Abstract. At present, there is no set strategy for the treatment of patients with colorectal cancer subsequent to the failure of standard treatment, other than the use of regorafenib (RGR) and TAS-102. The best order in which to use these drugs, and their safety and efficacy in combination with other drugs, are currently under investigation. It has been reported that RGR has a resensitizing effect on tumors that have previously failed to respond to anticancer drugs; this makes it a promising salvage therapy for colorectal cancer. The present report describes the results of a retrospective study on 17 patients with metastatic colorectal cancer who received RGR treatment following the failure of standard therapy. Following RGR failure, 71% of the patients were fit for further anticancer treatment, and these patients survived longer than those who did not receive further treatment. Furthermore, this intervention did not shorten the period of best supportive care. As a considerable number patients were fit for further anticancer therapy after RGR treatment, which resulted in prolonged survival without shortening the period of best supportive care, it may be beneficial for future research to focus on finding the optimal time at which to switch from RGR to further anticancer therapy.
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide (1) . At the time of diagnosis, >20% of patients have metastases, and one-third of patients develop metastatic recurrence following the initial surgery (2) . The majority of patients with recurrence cannot be cured and are treated with palliative chemotherapy, which has shown great progress in recent years. Two drug combinations, FOLFOX [oxaliplatin with 5-fluorouracil (5-FU) and folinic acid] and FOLFIRI (irinotecan with 5-FU and folinic acid), have demonstrated improved outcomes in these patients (3, 4) . A pooled analysis of phase III studies has shown that exposition to all three active drugs (5-FU, irinotecan, and oxaliplatin) during the course of treatment may be ideal for prolonging the survival of patients (5) . The median overall survival times of these patients can exceed 30 months following the adoption of a combination chemotherapy with molecular target therapies in the first-line setting (6, 7) .
Regorafenib (RGR) is an oral multikinase inhibitor that targets a broad spectrum of angiogenic and stromal kinases. In a well-designed, phase III, international clinical trial, RGR has been shown to prolong overall and progression-free survival times compared with placebos when used as a salvage therapy subsequent to standard treatment comprising 5-FU, irinotecan and oxaliplatin (8, 9) . In the CORRECT trial, 26% of the patients underwent another anticancer therapy following RGR treatment; however, the details of this were not reported (8) . To date there has been no comprehensive published evidence supporting other treatment following RGR failure in CRC. It has been reported that RGR may have a resensitizing effect on tumors that have previously failed to respond to anticancer treatments (10) . In a single-institution study, post-RGR treatment was administered to 32% of the patients, of which 35% responded to a re-challenge with a chemotherapy that was previously discontinued prior to RGR treatment (11) . Therefore, in the present study, the results of treatment after RGR failure in CRC were analyzed in our hospital, with the aim of identifying a suitable salvage treatment.
Patients and methods
Study design. This was a single-institutional retrospective study performed at Ina Central Hospital (Ina, Japan). All patients were treated by the authors named in this report. The patients' medical records were reviewed after all of the patients had died. This retrospective study was approved by the institutional review board, and the requirement to obtain patient consent was waived. Statistical analysis. The mean overall survival times from the start of RGR treatment (OS-1) and from the discontinuation of RGR treatment (OS-2) were measured. The data were compared with respect to the consecutive treatment following RGR failure by the Kaplan-Meier method with a log-rank test. The duration of BSC was compared using a Student's t-test. Statistical analysis was performed by JMP ® 13 software (SAS Institute Inc., Cary, NC, USA). All P-values were two-sided and P<0.05 was considered to indicate a statistically significant difference.
Results

Patient characteristics.
The clinicopathological characteristics of the patients are summarized in Table I . In total, 9 male and 8 female patients were included in the study, and the mean age was 64.2 years. Exon 2 of the KRAS gene was wild-type in 8 patients and mutated in 9. The primary tumors were located on the right side in 8 patients (including 2 in the transverse colon) and on the left in 10. The median duration of RGR treatment was 14.5 weeks. RGR dosages were adjusted during the treatment in all patients, and the mean relative dose intensity was 56.5%. Imaging revealed that RGR treatment did not lead to any complete or partial responses, as assessed using the Response Evaluation Criteria In Solid Tumors version 1.1 (12) .
According to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (13), no hematological toxicities of grade 3 or 4 were observed during RGR treatment. Non-hematological toxicities of grade 3 or 4 were observed in 9 patients (52.9%), including hand-foot syndrome (4 patients), hypertension (1 patient), myalgia (1 patient), liver dysfunction (1 patient), diarrhea (1 patient) and mucositis (1 patient). RGR was discontinued due to disease progression in 14 patients and non-hematological toxicities in 3.
At the point of RGR treatment discontinuation, 1 patient had an Eastern Cooperative Oncology Group performance status (PS) of 0, 14 had a PS of 1, and two had a PS of 2 (14). Metastatic tumors at three sites were detected in 2 patients, at two sites in 9 patients, and at one site in 6 patients ( Table I) .
The mean age, RGR treatment duration, and relative dose intensity did not differ significantly between the patients who underwent further anticancer treatment and those who received BSC following RGR (Table II) .
Treatment and responses following RGR failure. Subsequent to RGR failure, 5 patients were treated with capecitabine, 3 received TAS-102, 2 received 5-fluorouracil (5-FU)/leucovorin (LV), 1 received S1 with irinotecan, and 1 received FOLFOX (oxaliplatin with 5-FU and folinic acid). In addition, 7 of these patients also received bevacizumab, while cetuximab was administered in 1 patient along with 5-FU/LV (Table III) . In 7 patients (41.2%), a second additional treatment after RGR failure was administered, including TAS-102 in 2 patients, S1 in 2 patients, and capecitabine with irinotecan, capecitabine, and UFT each in 1 patient. The duration of treatment was 6.1 weeks on average. Additionally, 4 patients (23.5%) received a third treatment, of which only 1 patient was treated with S1 plus oxaliplatin for 14 weeks, and the others discontinued treatment within two weeks (Table IV) . In all patients who received chemotherapy following RGR failure, anticancer treatment was discontinued because of disease progression, and not PS deterioration. Imaging 
Discussion
Other than the use of RGR or TAS-102, there is no set strategy for the treatment of patients with metastatic CRC after the failure of standard treatment comprising fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and anti-epidermal growth factor receptor antibodies, (11, 15, 16) . As Masuishi et al (17) reported, improved salvage therapies are required for CRC. In their study, RGR and TAS-102 were effective and safe to use as salvage therapies; however, the most beneficial order in which to use these drugs remains to be clarified, and the heterogeneity of the population of patients receiving these therapies hampers attempts to answer this question (16) . It has been reported that RGR may have a resensitizing effect on tumors that have previously failed to respond to anticancer treatments (10) . Clinical trials to investigate the value of reusing a previously failed drug after RGR treatment are underway (8, 18) .
The current retrospective study showed that 70.5% of patients were fit for further anticancer treatment after RGR treatment, and these patients survived longer than those who did not receive further chemotherapy after RGR failure. Furthermore, the duration of BSC did not differ significantly between the patients who received anticancer therapy and those who did not. It is possible that the difference in survival time was due to the conditions of the individual patient: All patients in the BSC group were unfit for consecutive anticancer drug treatment following RGR discontinuation. Therefore, although the effectiveness of further anticancer treatment is unclear, further treatment confers a possible survival benefit for patients who are sufficiently fit at the point of RGR failure. RGR is not the final salvage treatment for CRC. Careful treatment to avoid adverse events is crucial, and accurate judgment may be required for discontinuing the anticancer treatment to maintain the quality of life of the patients.
In our institution, bevacizumab with fluoropyrimidines was the most frequently selected treatment regimen following RGR failure; however, the benefits of this approach over other regimens have not been evaluated. Biomarkers to enable clinicians to choose the optimal salvage therapy for CRC are necessary.
In conclusion, it will be beneficial for future research to establish an effective strategy for 'salvage' treatment for CRC, and to determine the optimal time during RGR treatment at which to switch to further anticancer therapy, as well as the order of treatment, without compromising the patients' quality of life towards the ends of their lives. Figure 1 . OS probability after start of RGR treatment (OS-1). OS-1 time was not significantly affected by consecutive anticancer treatment following RGR failure. OS, overall survival; RGR, regorafenib; BSC, best supportive care. Figure 2 . OS probability after discontinuance of RGR treatment (OS-2). OS-2 time was significantly longer in the group that received consecutive anticancer drug treatment after RGR failure. OS, overall survival; RGR, regorafenib; BSC, best supportive care. 
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